Surreal illustration of Urolithin A targeting pancreatic cancer cells.

Urolithin A: The Natural Compound Revolutionizing Pancreatic Cancer Research?

Lena Kashyap in Health & Wellness November 2025 • 4 min read.

"Discover how this pomegranate-derived compound targets a critical pathway in pancreatic cancer, offering new hope for treatment."

Pancreatic cancer, particularly pancreatic ductal adenocarcinoma (PDAC), remains one of the most challenging and deadly cancers to treat. With a five-year survival rate stubbornly below 9%, the disease often presents with advanced metastasis and resistance to conventional chemotherapies. For decades, researchers have been relentlessly searching for new therapeutic strategies to combat this aggressive malignancy, especially given the limitations and toxic side effects associated with current standard treatments like gemcitabine and FOLFIRINOX.

In recent years, natural compounds have garnered significant attention in cancer research, praised for their potential bioavailability, reduced toxicity, and cost-effectiveness compared to synthetic drugs. These compounds, often found in everyday foods, are being investigated for their antioxidant, anti-inflammatory, and antitumor properties. Population-based studies have hinted at an inverse relationship between the consumption of certain berries and a reduced incidence of pancreatic cancer, sparking interest in compounds like ellagic acid (EA), released from ellagitannins found in pomegranates, raspberries, and strawberries.

Now, a groundbreaking study has illuminated the potential of Urolithin A, a metabolite produced when EA is processed by gut microbiota. This novel compound, derived from pomegranates, is showing promise in targeting the PI3K/AKT/mTOR pathway, a critical signaling cascade involved in cancer cell growth and survival. The new research suggests Urolithin A could offer a new, more effective approach to pancreatic cancer treatment. It underscores the importance of natural compounds in addressing one of modern medicine’s toughest challenges.

How Does Urolithin A Target the PI3K/AKT/mTOR Pathway in Pancreatic Cancer?

Surreal illustration of Urolithin A targeting pancreatic cancer cells.

The study's findings reveal that Urolithin A (Uro A) significantly impacts the PI3K/AKT/mTOR pathway, which plays a pivotal role in the proliferation, survival, and metastasis of pancreatic cancer cells. Researchers demonstrated that treating PDAC cells with Uro A effectively blocked the phosphorylation of AKT and p70S6K, two key proteins within this pathway. This blockage was observed in vitro, suggesting a direct inhibitory effect on these critical signaling molecules.

To validate these in vitro observations, scientists conducted in vivo experiments using both xenograft models and genetically engineered mouse models (PKT mice) that develop spontaneous pancreatic tumors. The results were compelling: Uro A treatment not only inhibited tumor growth but also increased overall survival in the PKT mice. These results highlight the therapeutic potential of Urolithin A.

In Vitro Studies: Demonstrated that Urolithin A inhibits the phosphorylation of AKT and p70S6K in PDAC cells.
Xenograft Models: Showed a significant reduction in tumor growth in mice treated with Urolithin A.
PKT Mice Models: Revealed increased overall survival and attenuated tumor growth.

Further histological analysis confirmed that Uro A's actions were directly linked to decreased phosphorylation of AKT and p70S6K, reduced cellular proliferation, and increased apoptosis (programmed cell death) in both xenograft and PKT mouse models. These mechanistic insights solidify Uro A's potential as a therapeutic agent by directly interfering with cancer cell survival mechanisms.

The Future of Pancreatic Cancer Treatment: Is Urolithin A the Answer?

The findings from this research offer a beacon of hope in the ongoing battle against pancreatic cancer. Urolithin A's ability to target the PI3K/AKT/mTOR pathway, reduce tumor growth, and improve survival rates in preclinical models suggests it could become a valuable asset in future treatment strategies. As research progresses, the potential of Urolithin A as a therapeutic agent warrants further exploration, possibly leading to clinical trials and new dietary interventions.

About this Article -

This article was crafted using a human-AI hybrid and collaborative approach. AI assisted our team with initial drafting, research insights, identifying key questions, and image generation. Our human editors guided topic selection, defined the angle, structured the content, ensured factual accuracy and relevance, refined the tone, and conducted thorough editing to deliver helpful, high-quality information.See our About page for more information.

This article is based on research published under:

DOI-LINK: 10.1158/1535-7163.mct-18-0464, Alternate LINK

Title: Urolithin A, A Novel Natural Compound To Target Pi3K/Akt/Mtor Pathway In Pancreatic Cancer

Subject: Cancer Research

Journal: Molecular Cancer Therapeutics

Publisher: American Association for Cancer Research (AACR)

Authors: Tulasigeri M. Totiger, Supriya Srinivasan, Venkatakrishna R. Jala, Purushottam Lamichhane, Austin R. Dosch, Alexander A. Gaidarski, Chandrashekhar Joshi, Shobith Rangappa, Jason Castellanos, Praveen Kumar Vemula, Xi Chen, Deukwoo Kwon, Nilesh Kashikar, Michael Vansaun, Nipun B. Merchant, Nagaraj S. Nagathihalli

Published: 2019-02-01

Everything You Need To Know

What makes Urolithin A a compound of interest in pancreatic cancer research?

Urolithin A, a metabolite derived from pomegranates, is gaining attention because it targets the PI3K/AKT/mTOR pathway, which is critical for cancer cell growth and survival. This natural compound has shown potential in preclinical studies for inhibiting tumor growth and improving survival rates, offering a new avenue for pancreatic cancer treatment. Its origin from a natural source also suggests potential advantages in terms of bioavailability and reduced toxicity compared to traditional chemotherapies like gemcitabine and FOLFIRINOX, though further research is needed to confirm these benefits in clinical settings.

How does Urolithin A specifically affect the PI3K/AKT/mTOR pathway in pancreatic cancer cells?

Urolithin A inhibits the phosphorylation of AKT and p70S6K, which are two key proteins within the PI3K/AKT/mTOR pathway. By blocking the phosphorylation of these proteins, Urolithin A disrupts the signaling cascade that promotes cell proliferation, survival, and metastasis. This inhibitory effect has been observed in vitro and in vivo, leading to reduced tumor growth and increased apoptosis (programmed cell death) in preclinical models. This mechanism of action suggests that Urolithin A directly interferes with cancer cell survival mechanisms.

Can you elaborate on the in vivo studies that demonstrated the efficacy of Urolithin A against pancreatic cancer?

In vivo studies involved xenograft models and genetically engineered mouse models (PKT mice) that develop spontaneous pancreatic tumors. When these models were treated with Urolithin A, researchers observed a significant reduction in tumor growth. Notably, the PKT mice, which naturally develop pancreatic tumors, exhibited increased overall survival. Further histological analysis confirmed that Urolithin A's actions were linked to decreased phosphorylation of AKT and p70S6K, reduced cellular proliferation, and increased apoptosis (programmed cell death) in both xenograft and PKT mouse models. These results underscore Urolithin A's potential as a therapeutic agent by directly interfering with cancer cell survival mechanisms.

What are the broader implications of targeting the PI3K/AKT/mTOR pathway in cancer treatment, and how does Urolithin A fit into this context?

The PI3K/AKT/mTOR pathway is a central regulator of cell growth, proliferation, survival, and metabolism, making it a critical target in cancer therapy. Its dysregulation is implicated in various cancers, including pancreatic cancer. By targeting this pathway with Urolithin A, it's possible to disrupt multiple cancer-promoting processes simultaneously. While other inhibitors of this pathway exist, Urolithin A's natural origin and potential for reduced toxicity could offer advantages. However, the long-term efficacy, potential resistance mechanisms, and optimal delivery methods of Urolithin A still need to be thoroughly investigated in clinical trials.

Considering the research, what future directions are likely for Urolithin A in pancreatic cancer treatment?

Future research will likely focus on several key areas. Clinical trials are needed to evaluate the safety and efficacy of Urolithin A in human patients with pancreatic cancer. These trials will help determine the optimal dosage, delivery method, and potential side effects. Further studies are also warranted to explore Urolithin A's potential in combination with existing chemotherapies like gemcitabine and FOLFIRINOX, potentially leading to synergistic effects. Additionally, research may investigate the role of gut microbiota in Urolithin A production and its impact on treatment outcomes. Dietary interventions aimed at enhancing Urolithin A production through pomegranate consumption or supplementation could also be explored as a complementary approach to pancreatic cancer management.